Diabetes Trials

Radomized, double-blind, placebo-controlled study to investigate the effect of Lepodisiran on the reduction of major adverse cardiovascular events in adults with elevated lipoprotein(a) who have established cardiovascular disease or are at risk for a first cardiovascular event.
 

Randomized, double-blind, placebo-controlled study to investigate the effect of Retatrutide on the incidence of major adverse cardiovascular events and the decline in kidney function in participants with BMI >27kg and atherosclerotic cardiovascular disease and/or chronic kidney disease.